Stock Markets February 6, 2026

Roivant Shares Jump After Strong Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis

Positive BEACON data, plans for pivotal Phase 3 in 2026, and solid cash position drive investor reaction

By Priya Menon ROIV
Roivant Shares Jump After Strong Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis
ROIV

Roivant Sciences reported robust Phase 2 findings for brepocitinib in cutaneous sarcoidosis, prompting a 15% rise in its stock. The 45 mg dose produced a 22.3-point mean improvement on CSAMI-A at Week 16 versus 0.7 points for placebo, a statistically significant difference of 21.6 points. The company plans a Phase 3 program in 2026 and reported $4.5 billion in cash and equivalents as of December 31, 2025.

Key Points

  • Roivant stock rose 15% after positive Phase 2 brepocitinib data in cutaneous sarcoidosis.
  • Brepocitinib 45 mg produced a 22.3-point mean CSAMI-A improvement at Week 16 versus 0.7 points for placebo, a 21.6-point statistically significant difference.
  • Priovant will advance cutaneous sarcoidosis to a Phase 3 pivotal program beginning in 2026 after FDA engagement; Roivant reported $4.5 billion in cash and equivalents as of Dec. 31, 2025.

Roivant Sciences (NASDAQ:ROIV) saw its shares climb 15% after the company disclosed positive Phase 2 results for brepocitinib in cutaneous sarcoidosis, a condition noted in the trial for being highly resistant to treatment. The data, reported from the BEACON study, showed a marked clinical advantage over placebo for the 45 mg dose at the prespecified 16-week timepoint.

Specifically, brepocitinib 45 mg achieved a 22.3-point mean improvement in CSAMI-A (Cutaneous Sarcoidosis Activity and Morphology Instrument - Activity score) at Week 16, compared with a 0.7-point improvement in the placebo arm. That equates to a statistically significant treatment effect of 21.6 points in favor of brepocitinib on the primary efficacy measure.

Beyond the primary endpoint, the company reported that brepocitinib produced 100% response rates on multiple endpoints within the study population, despite enrolling patients characterized as highly treatment-resistant. Those response rates were highlighted by Roivant as notable given the refractory nature of the enrolled cohort.

Priovant, a Roivant subsidiary, intends to pursue a pivotal development path for cutaneous sarcoidosis, moving toward a Phase 3 program after engaging with the U.S. Food and Drug Administration. The company plans to initiate the Phase 3 study in 2026. This will be the third indication for brepocitinib to reach a pivotal-program stage, following a recent New Drug Application submission to the FDA for dermatomyositis.

The company also provided updates on other clinical programs. Roivant said its IMVT-1402 trial, targeting difficult-to-treat rheumatoid arthritis and described as potentially registrational, is now fully enrolled, with topline results expected in the second half of 2026. Separately, Pulmovant’s Phase 2 study of mosliciguat in pulmonary hypertension associated with interstitial lung disease has completed enrollment.

On its financial position, Roivant reported consolidated cash, cash equivalents, restricted cash and marketable securities totaling $4.5 billion as of December 31, 2025. The company stated that this liquidity supports its cash runway into profitability.

Commenting on the BEACON findings, Dr. Misha Rosenbach, Director of the Cutaneous Sarcoidosis Program at the Hospital of the University of Pennsylvania, said: "The BEACON study is a watershed moment for the sarcoidosis field, and most importantly, for our patients. This is the sort of data you dream of seeing when you look at trial results - and I would call this a transformational moment for sarcoidosis."

The clinical readout and the pathway toward a Phase 3 program, together with the company’s stated cash position, are the proximate drivers for the market reaction. Investors appear to have reacted to both the strength of the efficacy signal in a difficult-to-treat population and the visibility provided by the projected development timeline for brepocitinib.


What to watch next - Progression of the Phase 3 program planning following FDA engagement; timing and design details for the pivotal study; topline data timing for IMVT-1402 in difficult-to-treat rheumatoid arthritis expected in H2 2026; any updates on Pulmovant’s mosliciguat program.

Risks

  • Clinical development risk - Phase 2 results do not guarantee success in the planned Phase 3 program, which remains subject to FDA discussion and future trial outcomes (affecting biopharma and healthcare sectors).
  • Timing uncertainty - Topline data for IMVT-1402 are not expected until the second half of 2026, leaving an extended period before potential registration-readout events (impacting investor sentiment in biotech and capital markets).
  • Trial population considerations - The reported results come from a highly treatment-resistant cohort; how broadly the results translate to wider patient populations will depend on future studies (relevant to clinical adoption and commercial prospects).

More from Stock Markets

Jakarta Shares Finish Higher; IDX Composite Climbs 1.19% as Financials, Infrastructure and Agriculture Lead Feb 23, 2026 DAX Drops as U.S. Tariff Shift Rekindles Trade Uncertainty; STOXX Edges Lower Feb 23, 2026 European Markets Pull Back as Fresh U.S. Tariff Moves Undermine Risk Appetite Feb 23, 2026 Rolls-Royce Seeks UK Backing for £3 Billion UltraFan 30 Engine Programme Feb 23, 2026 Taiwan benchmark climbs to record as glass, plastics and cement groups lead gains Feb 23, 2026